| Date | Title | Description |
| 20.02.2023 | NFL Biosciences receives € 1.7 million in « Avance Innovation » funding from Bpifrance | - |
| 30.01.2023 | NFL Biosciences launches a round of fundraising for approximately 2.5 million euros | - |
| 25.08.2022 | 3T Biosciences Raises $40M in Series A Financing | Stefan Scherer, MD, PhD, 3T Biosciences president and CEO
3T Biosciences, a South San Francisco, CA-based immunotherapy company, raised $40M in Series A funding.
The round was led by Westlake Village BioPartners with participation from Ligh... |
| 26.05.2022 | Terremoto Biosciences Launches With $75M Series A |
SOUTH SAN FRANCISCO, CA, Terremoto Biosciences, a biotechnology company, has raised $75 million in a Series A financing co-led by OrbiMed and Third Rock Ventures.
>> Click here for more funding data on Terremoto Biosciences
>&g... |
| 26.05.2022 | Terremoto Biosciences launches with $75M | Terremoto Biosciences has raised a $75 million Series A led by OrbiMed and Third Rock Ventures. Based in the Bay Area, the biotech company uses covalent chemistry to develop small molecule medicines.
View details |
| 07.04.2022 | Codetta Biosciences Announces $15 Million in Series A Financing | We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT |
| 03.01.2022 | Amberstone Biosciences picks up $12M | Amberstone Biosciences has raised a $12 million Series A co-led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures. Founded in 2018, the Laguna Hillls, Calif.-based company is a developer of immunotherapeutics intended to treat s... |
| 30.11.2021 | Hollister Biosciences Announces Third Quarter Fiscal 2021 Financial Results Including Revenue of USD $14.5M and Adjusted Ebitda of USD $1.2M | Revenue of $14.5 million increased 53% from prior year period
Gross profit income of $3.5 million increased 151% from prior year period
Net income was $0.4 million versus a loss of $0.6 million in prior year period
Adjusted EBITDA was $1.2 ... |
| 16.11.2021 | Deka Biosciences Raises USD 20 Million in Series A Financing | GERMANTOWN, Md., Nov. 16, 2021 /PRNewswire/ -- Maryland-based biotech company Deka Biosciences ("Deka") today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors... |
| 09.11.2021 | Home Biosciences Closes $15 Million Seed Financing Led by Redmile Group and Sofinnova Partners | Home Biosciences, Europe’s first venture builder fully dedicated to biotech, announced today a $15 million Seed financing led by Redmile Group and Sofinnova Partners.
Home Biosciences is the partner of choice for academics and scientists to... |
| 12.10.2021 | Biotech startup AUM Biosciences raises $27 mn from Everlife and SGI | Biotech startup AUM Biosciences announced on Tuesday it has raised $27 million (around Rs 200 crore) in a Series A funding round from Singapore-based private equity fund Everlife and SPRIM Global Investments (SGI), a health science-focused ... |
| 15.09.2021 | Alamar Biosciences Completes $80M Series B Fundraising to Bring Unprecedented Performance to the Proteomics Market | - |
| 19.08.2021 | Cellectar Biosciences : Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia | FLORHAM PARK, N.J. - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, announced it has been awarded a peer-reviewed Na... |
| 18.08.2021 | Cellectar Biosciences : Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia | FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced... |
| 18.08.2021 | Cellectar Biosciences : Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia (Form 8-K) | Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia
FLORHAM PARK, N.J., August 18, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical ... |
| 12.08.2021 | Pressure BioSciences : New Eco-Friendly Agrochem Subsidiary Receives Over $1,000,000 in Orders in First Month of Operations | Pressure BioSciences New Eco-Friendly Agrochem Subsidiary Receives Over $1,000,000 in Orders in First Month of Operations
Download as PDFAugust 12, 2021
PBI Agrochem Integration into the Sales Channels of Its Planned Asset Acquisition of a ... |
| 30.06.2021 | Padres Biosciences raises $75M in a SPAC deal to be used for advance the development of its oral antiviral COVID-19 drug | - |
| 10.06.2021 | Senda Biosciences : Announces Closing of $98 Million Series B Financing | CAMBRIDGE, Mass., June 10, 2021 /PRNewswire/ -- Senda Biosciences, a company that is systematically harnessing the powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of... |
| 10.06.2021 | Senda Biosciences Announces Closing of $98 Million Series B Financing | |
| 05.05.2021 | BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company's Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs | |
| 22.03.2021 | Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock | |
| 19.02.2021 | Sciwind Biosciences Raises US$37M in Series B Financing | Hangzhou Sciwind Biosciences Co., Ltd., a Hangzhou, China-based clinical-stage biopharmaceutical company focusing on research and development of innovative biologics, closed a US$37M series B financing.
The round was led by LYFE Capital and... |
| 17.02.2021 | Kumquat Biosciences has raised a $50M financing round | - |
| 11.02.2021 | Willow Biosciences Announces Increase to Bought Deal Offering from $20.0 Million to $25.0 Million | NOT FOR DISTRIBUTION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW.
VANCOUVER, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Willow Biosciences Inc. ("Willow&q... |
| 15.01.2020 | Arpeggio Biosciences raises $3.2M in seed round | Arpeggio Biosciences Inc. raised $3.2 million in its seed round this week as part of its drug testing
The six-employee company, which lists its address at the same building as the University of Colorado Boulder’s BioFrontiers Institute, had... |
| 13.01.2020 | Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital a... | - |
| 11.12.2019 | Quellis Biosciences Raises $17 Million To Treat Rare Diseases | Biopharmaceutical company Quellis Biosciences announced it raised $17 million to treat serious rare diseases
Quellis, a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases — announced that it has em... |
| 05.12.2019 | Akoya Biosciences Raises $50M in Financing | Akoya Biosciences, Inc., a Menlo Park, Calif.-based spatial biology company, closed a $50m financing.
The round was led by Piper Jaffray Merchant Banking, a division of Piper Jaffray, with participation from Telegraph Hill Partners and new ... |
| 18.07.2019 |
Kumquat Biosciences Finds $47.0M
| San Diego-based Kumquat Biosciences, a new, stealth-mode biotechnology startup, has raised $47.0M in what appears to be the company's first funding round, with a target of $55M for the equity funding, according to a regulatory filing from t... |
| 23.01.2019 | Lindy Biosciences Raises $547,000 in Equity | Lindy Biosciences, a Research Triangle Park-based therapeutics company, has raised $547,000 in equity.
According to the Form D filed Tuesday, Lindy Biosciences must collect over $1 million in addition to sell its entire offering of $1.6 mil... |
| 15.01.2019 | Folium Biosciences Nabs $3M |
COLORADO SPRINGS, CO, Australis Capital, a cannabis-focused investment firm has provided $3 million to Folium Biosciences.
>> Click here for more funding data on Folium Biosciences
>> To export Folium Biosciences funding dat... |
| 15.05.2018 | With new $600M fund, CRV expands into bioengineering investment, adds strategic growth stage deals | In addition to bioengineering, Fund XVII will also invest in enterprise, consumer-centered companies, according to the blog entry.
Axios reported that the fund’s strategy actually marks a change from CRV’s initial plans to have a separate f... |
| 22.03.2018 | Durham-based Lindy Biosciences Raises $150,000 | Lindy Biosciences has raised $150,000, according to a filing with the Securities and Exchange Commission.
The money was raised by a single investor.
The Durham-based company produces development-stage protein therapeutic formulations.
Its c... |
| 13.10.2016 | TransThera Biosciences Raises Close to US$10M in Series A Financing | TransThera Biosciences Co. Ltd, a Nanjing, China-based biotech company specialized in developing novel NCE drugs, raised close to US$10M in Series A financing.
The round was led by Morningside Ventures.
Led by Dr. Frank Wu, Founder/CEO, a v... |
| 19.08.2016 | Avelas Biosciences Raises $20M Series C | - |
| 06.06.2016 | Vendanta Biosciences Lands $50M |
CAMBRIDGE, MA, Vedanta Biosciences, pioneering the development of a new class of therapies designed to modulate the human microbiome, today announced that it has raised $50 million in new equity investments.
>> Click here for more ... |
| 03.04.2015 | LinCor Biosciences Raises $500K | LinCor Biosciences, Pte. Ltd., a Singapore-based developer and manufacturer of bioengineered corneas, raised $500k in funding.
The Indiana Lions Eye Bank, Indianapolis, IN, USA, made the investment.
The company intends to use the funds to a... |
| 02.03.2015 | Vigilant Biosciences Raises $5.5 Million In Series B Funding | Miami, Florida based Vigilant Biosciences is a leading high-tech healthcare company that focuses on early detection and intervention of cancer. Vigilant Biosciences has raised $5.5 million in Series B funding from White Owl Capital Partners... |
| 01.01.2015 | 3-V Biosciences Closes $28.5M in Series D Funding | 3-V Biosciences, a Menlo Park, Calif.-based biopharmaceutical company, closed $28.5m in Series D funding.
The round was led by New Enterprise Associates, Kleiner Perkins Caufield & Byers and Rock Springs Capital Management with particip... |
| 22.09.2014 | Thyritope Biosciences Secures $10M in Series A |
SAN DIEGO, CA, Thyritope Biosciences will receive up to $10 million in Series A financing and R&D support from Avalon Ventures and GSK.
>> Click here for more funding data on Thyritope Biosciences
>> To export Thyritope ... |
| 22.09.2014 | Thyritope Biosciences to Receive up to $10M in Series A Financing | Thyritope Biosciences, Inc., a San Diego, CA-based developer of therapeutics that target thyroid stimulating auto-antibodies, will receive up to $10m in Series A financing and R&D support.
Backers included Avalon Ventures and GlaxoSmith... |
| 05.06.2014 | Ibis Biosciences Gets $7.2M Contract for Biosensor System | The Defense Advanced Research Projects Agency awarded Ibis Biosciences Inc., the Carlsbad-based unit of Abbott Laboratories, a $7.2 million contract to develop its PUMA Biosensor system.
The Pentagon announced the award June 3. Work will be... |
| 12.02.2014 | Sedia Biosciences Receives $1.0 Million NIH Grant for New HIV Diagnostic Assay | Project would expand application of Sedia’s HIV-1 LAg-Avidity EIA from incidence measurement in populations to individual diagnostic use determining recency of HIV-1 infection
PORTLAND, Ore.–(BUSINESS WIRE)–February 12, 2014–
Sedia Bioscien... |
| 03.07.2013 | Blaze Biosciences ropes in $8.1M for tumor targeting “paint” | Blaze Biosciences is more than halfway to a targeted $15 million in a Series B round to fund its Tumor Paint, a surgical tool that visually distinguishes solid tumor cells from healthy cells.
Founded in 2010, the Seattle, Wash.-based Blaze ... |
| 22.06.2013 | 3-V Biosciences Completes $20M Series C Financing | 3-V Biosciences, Inc., a Menlo Park, California-based biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, completed a $20m Series C financing round.
Backers included existing inve... |
| 08.05.2013 | Cardio3 BioSciences Raises €19M in Equity Funding | Cardio3 BioSciences, a Mont-Saint-Guibert, next to Louvain-La-Neuve, Belgium-based biotechnology company, raised €19m in equity funding.
Of the €19m raised, €7m is in new equity committed by existing investors with €12m resulting from the c... |
| 05.01.2012 | 3-V Biosciences Closes $20M Financing | 3-V Biosciences, Inc. a Menlo Park, California-based biopharmaceutical company dedicated to discovering, developing and commercializing novel antiviral therapeutics that target host cell factors required for viral infection, closed a $20m f... |
| 07.12.2009 | Cell Biosciences Raises $4M and Acquires Protein Forest | Cell Biosciences, Inc., a Santa Clara, CA-based life science company, raised $4m in an equity financing led by Novo A/S.
The company has also acquired Protein Forest, Inc. a Lexington, Massachusetts-based developer of a sample preparation t... |
| 09.11.2009 | Belgium, Promethera® Biosciences Raises €5.3M Series A Financing | Promethera® Biosciences, a Louvain, Belgium-based stem cell therapy company, announced the closing of a €5.3m Series A equity financing round.
The investor syndicate was led by Vesalius Biocapital (Belgium) and included SRIW, Life Sciences ... |
| 19.08.2009 | Cleveland synchrotron biosciences center receives $4 million grant | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermin... |
| 20.07.2009 |
Numira Biosciences Gets $3.2M
| Irvine-based Numira Biosciences, a contract research organization focused on high resolution imaging, has raised $3.2M in a funding round, according to a recent regulatory filing by the firm. No details on the funding have been announced by... |
| 25.08.2008 | IFCI Venture Capital Invests $4.6M In Marck Biosciences | IFCI Venture Capital (IVCL) has invested $4.6 million (Rs 20 crore) in Ahemadabad-based Marck Biosciences Ltd. The company is involved in manufacturing of sterile dosage products and with this round of funding plans to open up a new plant. ... |
| 16.06.2008 | Neodyne Biosciences raises $1M for plastic surgery wound care | A stealthy Palo Alto, Calif. startup called Neodyne Bioscences has raised $1 million from the Freidenrich Family Trust, according to a regulatory filing obtained by VentureBeat.
Neodyne was started by doctors at Stanford University. It’s wo... |
| 25.07.2007 | Alacrity Biosciences takes $4.9M as bridge to tackle eye disease | Alacrity Biosciences, a Laguna Hills, Calif., biotech developing eye treatments, raised $4.9 million in bridge financing while it gathers clinical data in support of a larger first round later this year, VentureWire reports (subscription re... |
| 21.03.2007 |
Numira Biosciences Gets $2.5M in Series A
| vSpring Capital, the Tech Coast Angels, and the Pasadena Angels have funded Irvine-based Numira Biosciences, Numira said this morning. The Series A round was worth $2.5M. Numira develops R&D tools focused on genetics and molecular imagi... |
| - | 3T Biosciences | “We are solving a major bottleneck in the field of targeted biotherapeutics in oncology – the identification of novel targets for the treatment of solid tumors.” |
| - | With new $600M fund, CRV expands into bioengineering investment, adds strategic growth stage deals | Early stage venture capital firm CRV has closed a $600 million fund that accomplishes a couple of firsts for the venture firm. The fund will embrace strategic growth stage investments as well as early-stage deals and adds bioengineering to ... |
